SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabets quarterly results sparked debate over softer Search and advertising growth and heavy AI infrastructure spending, which pushed free cash flow negative despite Google Cloud revenue more than doubling. Traders are split between viewing the cash burn and rising future capex as reasons for concern and treating the selloff as a buying opportunity given strong cloud growth and the companys longer-term AI prospects.

Alphabet Inc - Ordinary Shares - Class C

Alphabets earnings miss and heavy AI infrastructure spending, which pressured cash flow, drove the selloff. Traders are divided over whether uncertain returns on AI investment and search competition outweigh strong cloud growth, with some seeing the decline as a buying opportunity.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNows mixed quarterly results and softer fourth-quarter contracted-growth outlook have driven a sharp selloff, despite stronger revenue and a raised AI target. Traders are split between viewing the reaction as an overdone response to a modest earnings miss and seeing the outlook slowdown, high valuation, and AI-related software risks as reasons for caution.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances announcement of positive Phase 2 lifileucel data in previously treated metastatic non-small cell lung cancer, with a webcast to discuss the results and its precision-medicine strategy, is driving attention. Traders are largely enthusiastic about expanding the TIL therapy beyond melanoma, while speculation about a short squeeze and the results significance remains unconfirmed.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

Alphabets earnings miss and heavy AI-investment concerns dominated discussion of QQQ, with traders debating whether the results signal broader pressure on tech or create a buying opportunity; strong Microsoft results offered a counterpoint. The Feds rate decision and upcoming inflation data also added to uncertainty.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Reports that Marvell is in advanced talks to acquire Lumentum are driving attention, though no deal is final. Traders are split between optimism about a potential takeover and skepticism about the rumor and how Marvell could finance a transaction, fueling sharp volatility.

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.

Bausch Health Companies Inc

Bausch Healths better-than-expected third-quarter results and raised outlook are driving the rally, with traders also noting a share-repurchase authorization. The reaction is broadly bullish, though some see the move as a swing trade and remain cautious about the companys substantial debt and whether gains will hold.

Fortinet, Inc. provides cybersecurity solutions to a variety of businesses, such as enterprises, communication service providers, government organizations, and small to medium-sized businesses. Its product portfolio includes network security, secure access service edge, enterprise networking, security operations, application security, and operational technology. The company was founded by Ken Xie and Michael Xie in November 2000 and is headquartered in Sunnyvale, CA.

Fortinet Inc

Fortinets quarterly results triggered a sharp selloff despite beating headline estimates and raising its overall outlook; traders focused on slowing product growth, weaker service-revenue guidance, and gross-margin pressure against high expectations. The community is split between calling the drop an overreaction and viewing it as a valuation reset, while the decline also weighed on other cybersecurity stocks.

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AMGEN Inc.

Positive Phase 3 results for dazodalibep in Sjgrens disease, with the primary endpoint met, are drawing attention alongside Amgens recent share-price highs. Traders are weighing the pipeline news and momentum against upcoming earnings and questions about how much the data may add to the companys growth outlook.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Vikings quarterly update and CEOs estimate of roughly 2.5 years to a potential VK2735 launch prompted frustration over the commercialization timeline, cash burn, and whether management will pursue a partnership or go it alone. Some traders view the timeline as realistic while remaining bullish on the obesity-drug pipeline and Phase 3 progress.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$IREDA.NSE  
Cmp: 132 
Targets: 175-210 
Stoploss: 105 
Timeframe: 1 year 
Stock is consolidating near the support Zone. Considering the price action pullback is expected from the current level. 
$NIFTY50.NSE $NIFTY500.NSE

Sainath Aluru

RONIT GHADIGAONKAR

Vedh Anandh

Bala Yogesh

VINITH KUMAR D

abhisekh pandey

Stocktwits India

aboli h

Panneer Selvam

Nisha Ajith

mohammad shadab

FIIDII Data

Suraj Kumar

Chirag Malhotra

AmbushTrader276

letstrade04

Nitin Naik

vivek pandya

Yogesh Sharma

Girja

Shivam Shah

Nikhil N Gurav

Brijesh Kumar

Anand Yadav

Navya

Krunal Dekivadiya

StockTwits for iOS

And, $IREDA.NSE hit the targets of @MBA_INVESTMENTWALA 🎯

StockTwits Web

$IREDA.NSE : 65% ⬆️
$NIFTY50.NSE $NIFTY500.NSE

StockTwits For Android 

Aditya Hujband

$IREDA.NSE : +38% ⬆️

$NIFTY50.NSE $NIFTY500.NSE  @StocktwitsIndia

$NIFTY50.NSE $NIFTY500.NSE $IREDA.NSE  
IREDA: 176 (33%🚀) 
Done with the 1st Target 💯

$IREDA.NSE $NIFTY50.NSE $NIFTY500.NSE  

IREDA: +21% 🚀

$IREDA.NSE : 13% 🚀 
$NIFTY50.NSE $NIFTYBANK.NSE

Anuj Sanghvi

Nifty 50 is drawing attention amid a volatile recovery from its recent correction, with traders debating whether higher lows and inter-index divergences mark a potential bullish reversal or whether rallies remain vulnerable to renewed selling. The outlook is largely technical and confirmation-dependent; earlier weakness was also linked in the discussion to elevated crude prices and foreign investor outflows.

Nifty 500

Indian Renewable Energy Development Agency Ltd.

  
Cmp: 132 
Targets: 175-210 
Stoploss: 105 
Timeframe: 1 year 
Stock is consolidating near the support Zone. Considering the price action pullback is expected from the current level. 


This account has been verified as a SEBI Research Analyst (RA).

Verified SEBI RA Account

@MBA_INVESTMENTWALA someone saying nifty and bank nifty is overvalued  and anytime correction may come ...  If correction comes then IREDA also will correct  so now buying is good or have to wait till correction over .

 someone saying nifty and bank nifty is overvalued  and anytime correction may come ...  If correction comes then IREDA also will correct  so now buying is good or have to wait till correction over .